Exact Sciences Corporation (NASDAQ:EXAS) has earned an average rating of “Buy” from the seventeen research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $40.82.

Several equities research analysts have issued reports on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $25.00 price target on shares of Exact Sciences Corporation in a research note on Wednesday, April 26th. Cowen and Company lifted their price target on shares of Exact Sciences Corporation from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, May 15th. Leerink Swann set a $38.00 price target on shares of Exact Sciences Corporation and gave the company a “buy” rating in a research note on Friday, April 28th. Vetr lowered shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating and set a $36.37 price target on the stock. in a research note on Thursday, July 6th. Finally, Roth Capital reiterated a “buy” rating and issued a $40.00 price target (up from $33.00) on shares of Exact Sciences Corporation in a research note on Thursday, June 1st.

WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/exact-sciences-corporation-nasdaqexas-receives-consensus-recommendation-of-buy-from-analysts.html.

In related news, CFO Jeffrey Thomas Elliott sold 5,846 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $39.41, for a total transaction of $230,390.86. Following the completion of the sale, the chief financial officer now owns 19,861 shares of the company’s stock, valued at approximately $782,722.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP D Scott Coward sold 1,987 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $35.21, for a total transaction of $69,962.27. Following the sale, the senior vice president now directly owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The disclosure for this sale can be found here. Insiders own 4.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. OxFORD Asset Management LLP bought a new stake in shares of Exact Sciences Corporation during the second quarter valued at approximately $5,846,000. Dimensional Fund Advisors LP bought a new stake in shares of Exact Sciences Corporation during the second quarter valued at approximately $3,939,000. Renaissance Technologies LLC increased its stake in shares of Exact Sciences Corporation by 130.2% in the second quarter. Renaissance Technologies LLC now owns 808,600 shares of the medical research company’s stock valued at $28,600,000 after buying an additional 457,300 shares during the last quarter. Advisor Group Inc. increased its stake in shares of Exact Sciences Corporation by 0.8% in the second quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock valued at $270,000 after buying an additional 65 shares during the last quarter. Finally, Suntrust Banks Inc. increased its stake in shares of Exact Sciences Corporation by 7.5% in the second quarter. Suntrust Banks Inc. now owns 19,869 shares of the medical research company’s stock valued at $702,000 after buying an additional 1,391 shares during the last quarter. 84.86% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Corporation (EXAS) traded up 1.92% during trading on Friday, hitting $37.76. 1,183,339 shares of the stock were exchanged. The firm’s market capitalization is $4.50 billion. The stock has a 50 day moving average price of $37.62 and a 200-day moving average price of $28.82. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $42.18.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The firm had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. On average, equities research analysts anticipate that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.